Collaboration Initial Public Offering Pharmaceutical 
Cooley M&A
JANUARY 25, 2023
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.
Cooley M&A
JANUARY 23, 2024
While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Collaborate or buy?’ Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.
Expert insights. Personalized for you.
40 
Let's personalize your content